PriceTargets.com logo

Henry Schein - HSIC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $81.09
  • Forecasted Upside: 15.51%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$70.20 As of 04/17/2024 01:00 AM ET
▼ -1.02 (-1.43%)

This chart shows the closing price for HSIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Henry Schein Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSIC

Analyst Price Target is $81.09
▲ +15.51% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Henry Schein in the last 3 months. The average price target is $81.09, with a high forecast of $96.00 and a low forecast of $65.00. The average price target represents a 15.51% upside from the last price of $70.20.

This chart shows the closing price for HSIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Henry Schein. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
10/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
1/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/23/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
7/22/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
10/20/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
1/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/6/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$82.00 ➝ $88.00Low
3/6/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$74.00 ➝ $81.00Low
2/28/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$79.00 ➝ $83.00Low
2/28/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$82.00 ➝ $90.00Low
2/26/2024Leerink PartnrsReiterated RatingMarket PerformLow
2/26/2024Piper SandlerBoost TargetOverweight ➝ Overweight$78.00 ➝ $86.00Low
2/26/2024SVB LeerinkInitiated CoverageMarket Perform$78.00Low
12/12/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$71.00 ➝ $82.00Low
11/27/2023Stifel NicolausReiterated RatingBuy ➝ Buy$75.00Low
11/14/2023UBS GroupLower TargetNeutral ➝ Neutral$82.00 ➝ $75.00Low
11/14/2023Barrington ResearchLower TargetOutperform ➝ Outperform$90.00 ➝ $82.00Low
11/14/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$69.00 ➝ $65.00Low
11/10/2023Stifel NicolausUpgradeHold ➝ Buy$70.00Low
11/1/2023Stifel NicolausLower TargetHold ➝ Hold$80.00 ➝ $70.00Low
10/26/2023Piper SandlerLower TargetOverweight ➝ Overweight$94.00 ➝ $84.00Low
8/9/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$80.00 ➝ $83.00N/A
8/8/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$90.00Low
8/8/2023Stifel NicolausLower Target$85.00 ➝ $80.00Low
8/8/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$96.00Low
8/7/2023Bank of AmericaLower Target$76.00 ➝ $75.00Low
5/10/2023Barrington ResearchLower Target$92.00 ➝ $90.00Low
3/7/2023UBS GroupBoost TargetNeutral$75.00 ➝ $82.00Low
2/28/2023Credit Suisse GroupLower TargetOutperform$99.00 ➝ $97.00Low
2/21/2023Morgan StanleyLower TargetUnderweight$70.00 ➝ $69.00Low
2/17/2023Barrington ResearchLower TargetOutperform$99.00 ➝ $92.00Low
2/6/2023Piper SandlerBoost TargetOverweight$85.00 ➝ $97.00Low
12/21/2022Morgan StanleyLower TargetUnderweight$72.00 ➝ $70.00Low
11/1/2022William BlairReiterated RatingMarket PerformLow
9/26/2022Piper SandlerLower TargetOverweight$96.00 ➝ $85.00Low
8/9/2022Evercore ISILower Target$83.00Low
8/8/2022UBS GroupUpgradeSell ➝ Neutral$80.00Low
8/3/2022Credit Suisse GroupLower TargetOutperform$100.00 ➝ $90.00Low
8/3/2022Barrington ResearchLower TargetOutperform$102.00 ➝ $99.00Low
8/2/2022Piper SandlerLower Target$100.00 ➝ $96.00Low
7/21/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$93.00 ➝ $85.00Low
6/17/2022Stifel NicolausLower Target$90.00 ➝ $80.00Medium
6/14/2022Robert W. BairdDowngradeOutperform ➝ Neutral$103.00 ➝ $88.00High
5/3/2022William BlairReiterated RatingMarket PerformHigh
2/16/2022Barrington ResearchBoost Target$96.00 ➝ $102.00High
2/16/2022Morgan StanleyBoost TargetUnderweight$67.00 ➝ $72.00High
2/16/2022Robert W. BairdBoost Target$98.00 ➝ $103.00High
2/16/2022Credit Suisse GroupBoost TargetOutperform$90.00 ➝ $100.00High
1/31/2022Morgan StanleyInitiated CoverageUnderweight$67.00Low
1/28/2022Piper SandlerLower Target$98.00 ➝ $95.00Low
1/7/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$78.00 ➝ $90.00Low
11/3/2021Robert W. BairdBoost TargetOutperform$94.00 ➝ $98.00Low
11/2/2021Piper SandlerBoost TargetOverweight$95.00 ➝ $98.00Low
8/4/2021Barrington ResearchBoost TargetOutperform$91.00 ➝ $95.00High
8/3/2021Piper SandlerBoost TargetOverweight$89.00 ➝ $95.00High
5/5/2021Barrington ResearchBoost TargetOutperform$80.00 ➝ $91.00Low
5/5/2021Robert W. BairdBoost TargetOutperform$79.00 ➝ $90.00Medium
5/4/2021Piper SandlerBoost TargetOverweight$79.00 ➝ $89.00Medium
2/18/2021Barrington ResearchBoost TargetOutperform$72.00 ➝ $80.00High
2/8/2021Piper SandlerReiterated RatingOverweight$83.00Low
1/4/2021Robert W. BairdUpgradeNeutral ➝ Outperform$70.00 ➝ $79.00N/A
11/3/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$72.00Medium
5/7/2020UBS GroupLower TargetSell$60.00 ➝ $50.00High
5/6/2020Robert W. BairdBoost TargetNeutral$58.00 ➝ $60.00Low
5/6/2020Barrington ResearchDowngradeOutperform ➝ Market PerformMedium
5/5/2020CfraLower TargetHold$69.00 ➝ $60.00Medium
4/19/2020Credit Suisse GroupReiterated RatingHold$59.00Low
4/7/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$64.00 ➝ $59.00Low
4/2/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$68.00Medium
3/31/2020BarclaysLower TargetEqual Weight$58.00 ➝ $57.00Medium
3/20/2020BarclaysReiterated RatingHold$58.00High
2/24/2020JPMorgan Chase & Co.Boost TargetNeutral$66.00 ➝ $68.00Medium
1/9/2020Bank of AmericaDowngradeNeutral ➝ Underperform$65.00High
1/3/2020Evercore ISIDowngradeIn-Line ➝ UnderperformLow
1/2/2020Robert W. BairdDowngradeOutperform ➝ NeutralLow
12/3/2019Bank of AmericaBoost TargetNeutral$69.00 ➝ $71.00Low
11/11/2019Piper Sandler CompaniesBoost TargetOverweight$72.00 ➝ $80.00Low
11/6/2019Barrington ResearchReiterated RatingBuy$75.00Low
8/7/2019Barrington ResearchReiterated RatingBuy$75.00Medium
8/7/2019William BlairDowngradeOutperform ➝ Market PerformHigh
5/30/2019Wolfe ResearchInitiated CoverageUnderperform ➝ UnderperformLow
5/15/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$75.00 ➝ $70.00Low
5/8/2019Barrington ResearchBoost TargetOutperform$72.00 ➝ $75.00Medium
5/8/2019Craig HallumReiterated RatingBuy$72.00 ➝ $77.00High
4/17/2019GuggenheimInitiated CoverageBuy ➝ Buy$72.00Medium
(Data available from 4/17/2019 forward)

News Sentiment Rating

1.02 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2023
  • 17 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2023
  • 4 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
Mentions as of
11/19/2023
  • 13 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2023
  • 15 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/18/2024
  • 19 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2024
  • 34 very positive mentions
  • 25 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
3/18/2024
  • 21 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2024

Current Sentiment

  • 21 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Henry Schein logo
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Read More

Today's Range

Now: $70.20
Low: $70.19
High: $71.92

50 Day Range

MA: $74.53
Low: $70.20
High: $80.57

52 Week Range

Now: $70.20
Low: $60.01
High: $85.39

Volume

1,067,027 shs

Average Volume

1,112,613 shs

Market Capitalization

$9.02 billion

P/E Ratio

22.29

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Henry Schein?

The following equities research analysts have issued research reports on Henry Schein in the last twelve months: Bank of America Co., Barrington Research, Credit Suisse Group AG, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partnrs, Morgan Stanley, Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, and UBS Group AG.
View the latest analyst ratings for HSIC.

What is the current price target for Henry Schein?

11 Wall Street analysts have set twelve-month price targets for Henry Schein in the last year. Their average twelve-month price target is $81.09, suggesting a possible upside of 15.5%. Credit Suisse Group AG has the highest price target set, predicting HSIC will reach $96.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $65.00 for Henry Schein in the next year.
View the latest price targets for HSIC.

What is the current consensus analyst rating for Henry Schein?

Henry Schein currently has 1 sell rating, 5 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HSIC, but not buy more shares or sell existing shares.
View the latest ratings for HSIC.

What other companies compete with Henry Schein?

Other companies that are similar to Henry Schein include Patterson Companies, Repligen, Legend Biotech, Chemed and Qiagen. Learn More about companies similar to Henry Schein.

How do I contact Henry Schein's investor relations team?

Henry Schein's physical mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company's listed phone number is (631) 843-5500 and its investor relations email address is [email protected]. The official website for Henry Schein is www.henryschein.com. Learn More about contacing Henry Schein investor relations.